Market Overview

Grifols to Acquire Transfusion Diagnostics Business of Novartis for $1,675M

Related GRFS
33 Stocks Moving In Friday's Pre-Market Session
Rigel Rises On European Marketing Agreement For Autoimmune Drug

Grifols (NASDAQ: GRFS), a global healthcare company and leading producer of plasma therapies, and Novartis (NYSE: NVS), today announced that they have signed a definitive agreement whereby Grifols will acquire the transfusion diagnostics unit of Novartis for a total amount of US$1,675 million (€1,240 million). 

The transaction is part of Grifols' growth

See full press release

Posted-In: Earnings News Guidance Asset Sales Management M&A Global


Related Articles (NVS + GRFS)

View Comments and Join the Discussion!

Transocean Enters Agreement With Icahn Group

Shire to Acquire ViroPharma for $50.00/Share in Cash